125 results on '"de Castro, J."'
Search Results
2. P2.14-01 Patient-Reported Outcomes from IMfirst: Chemotherapy Plus Atezolizumab in a Real-World Setting of Extensive-Stage SCLC
3. P2.14-04 Treatment Beyond Progression with Atezolizumab in Extensive-Stage SCLC: Exploratory Analysis from the IMfirst Study
4. P1.27-07 BRAF Mutations Identify Non-small-Cell Lung Cancer Patients Who Benefit from Neoadjuvant Chemo-Immunotherapy
5. Risk of detecting prostate cancer based on the PSAD and PIRADS lesions in MRI in patients with a negative previous biopsy.
6. Quality of life in patients with Non-Muscle Invasive Bladder Cancer (NMIBC) subjected to intravesical instillations with BCG induction
7. Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1
8. Macrophage cell membrane infused biomimetic liposomes for glioblastoma targeted therapy
9. PP01.17 Sotorasib in Advanced KRAS p.G12C–Mutated NSCLC with Treated or Untreated Brain Metastases: Safety and Efficacy Data from the Global Expanded Access Program (EAP)
10. EE495 Cost-Effectiveness Analysis of Adjuvant Atezolizumab Versus Best Supportive Care in the Treatment of Patients With Resectable Early-Stage Non-Small Cell Lung Cancer and PD-L1≥50% Expression
11. Prostate rebiopsy in patients with a negative previous biopsy and MRI. When should it be done?
12. PL03.12 Progression Free Survival and Overall Survival in NADIM II Study
13. EP08.02-131 Alectinib after Crizotinib Failure in Patients with Advanced ALK-Positive NSCLC: Results from the Spanish Early Access Program
14. MA06.03 Pre-treatment ctDNA Levels Significantly Predicts of OS and PFS in NADIM II Trial
15. 989P Sotorasib in advanced KRAS p.G12C-mutated non-small cell lung cancer (NSCLC): Safety and efficacy data from the global expanded access program (EAP)
16. P2.07-02 RET Fusion Testing with FISH and Real-Time PCR: a Comparison with RNA-Based Next-Generation Sequencing in RET Positive NSCLC
17. EP08.01-049 Unscheduled Hospitalizations in Patients With Thoracic Tumors in the Era of Immunotherapy
18. Nefrectomía parcial y radical laparoscópica en tumores renales cT1. Análisis comparativo de complicaciones y supervivencia
19. Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC—a systematic review and meta-analysis
20. Laparoscopic nephron sparing surgery and radical nephrectomy in cT1 renal tumors. Comparative analysis of complications and survival
21. 32P Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC: A systematic review and meta-analysis
22. Study of the immunologic response of marine-derived collagen and gelatin extracts for tissue engineering applications
23. Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer
24. A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial
25. Development of a predictive model for optimizing the selection of patients for second transurethral resection bladder (TURB)
26. Renal tumors with left renal vein tumoral thrombosis. Is Preoperative Renal Artery Embolization (PRAE) helpful?
27. OA20.02 Pre-Treatment Levels of ctDNA for Long-Term Survival Prediction in Stage IIIA NSCLC Treated With Neoadjuvant Chemo-Immunotherapy
28. MA14.02 RET Fusion Testing in Advanced Non-Small Cell Lung Carcinoma Patients: the RETING Study
29. OA20.01 Long Term Survival in Operable Stage Iiia Nsclc Patients Treated With Neoadjuvant Nivolumab Plus Chemotherapy - Nadim Study
30. Biomimetic and cell-based nanocarriers – New strategies for brain tumor targeting
31. VP3-2021: A randomized phase II study of second-line osimertinib (Osi) and bevacizumab (Bev) versus Osi in advanced non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and T790M mutations (mt): Results from the ETOP BOOSTER trial
32. Which ultrasound or MRI characteristics demonstrate the highest diagnostic accuracy in identifying malignancy in males with indeterminate lesions of the testis? A systematic review
33. Comparación entre prostatectomía laparoscópica y abierta: análisis de la evolución oncológica
34. Comparison between laparoscopic and open prostatectomy: Oncological progression analysis
35. Genomic profiling in non-small-cell lung cancer in young patients. A systematic review
36. Survival analysis of patients with prostate cancer and unfavorable risk factors treated with radical prostatectomy and salvage radiotherapy after biochemical recurrence and persistence
37. Análisis de supervivencia de los pacientes con cáncer de próstata con factores patológicos desfavorables tratados con prostatectomía radical y radioterapia de rescate tras la recidiva y persistencia bioquímica
38. PCN90 Economic IMPACT of the NSCLC Molecular Diagnosis in Spain: A Retrospective Analysis of Healthcare Resources Use and Associated Costs from the LUNG-One Study
39. External iliac artery dissection with prosthesis replacement in renal transplantation
40. Disección de arteria ilíaca externa con sustitución protésica en trasplante renal
41. Evaluación de los patrones de recurrencia por grupos de riesgo tras nefrectomía por cáncer renal
42. Analysis of recurrence trends according to risk groups after renal cancer nephrectomy
43. Relapse-free survival in high-risk prostate cancer after radical prostatectomy and salvage radiotherapy compared to radiotherapy plus primary hormone therapy
44. An individual patient data (IPD) prognostic factor study on the value of pathological factors in clinical stage I seminoma testis patients under active surveillance from the EAU Testicular Cancer Guidelines panel
45. Oncological control in high-risk prostate cancer after radical prostatectomy and salvage radiotherapy compared to radiotherapy plus primary hormone therapy
46. Risk model- recurrence risk groups for patients with localised renal cell carcinoma
47. Comparación del rendimiento entre biopsia transrectal clásica y biopsia «cognitiva» ecodirigida en la rebiopsia de la próstata
48. Comparison of classical transrectal prostate biopsy versus cognitive registration in rebiopsy
49. Retrospective study about lung carcinoid: Our experience in a Spanish hospital
50. Influencia de la extensión tumoral venosa en la recidiva local y a distancia de los tumores renales en un estadio pT3a pN0 cM0
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.